Proellex telapristone regulatory update

Repros said FDA provided guidance for the company's clinical program for low-dose oral Proellex telapristone to treat uterine fibroids and endometriosis, while remaining on a partial clinical hold.

Read the full 283 word article

How to gain access

Continue reading with a
two-week free trial.